The Predictive Value of Serum C-Reactive Protein (Crp) Levels in Untreated Prostatic Cancer
C-reactive protein (CRP) is an acute phase reactant protein (APRP). The APRP’s are a group of mainly glycoproteins which alter their plasma concentrations in response to a variety of stimuli including tissue injury, acute and chronic inflammation, connective tissue disease and cancer (1–3). Most of them are also influenced by oestrogens, which are often employed therapeutically in the management of prostatic cancer. CRP differs from the others in this respect (4). Plasma concentrations are, however, elevated as tumour burden increases (5). This present study evaluates the pre-treatment levels of CRP and serum acid phosphatase (SAP) in patients with benign prostatic hyperplasia and carcinoma of the prostate to determine the prognostic value of these tumour markers in the management of malignant prostatic disease.
KeywordsProstate Cancer Benign Prostatic Hyperplasia Connective Tissue Disease Single Radial Immunodiffusion Tumour Burden Increase
Unable to display preview. Download preview PDF.
- 1.C.L. Fischer and C.W. Gill, Acute Phase Proteins, in “Serum Abnormalities, Diagnostic and Clinical Aspects”, E.S. Ritzman and J.C. Daniels (eds), Little Brown and Co, Boston (1975) p.331.Google Scholar
- 5.J. Kohn, M. Hernandez and P.G. Riches, The Value of Acute Phase Reactants in the Management of the Disease, La Ricerca in Clin-ica e in Laboratorio, 8:61 (1978).Google Scholar
- 7.M.A. Andersch and A.J. Szczypinski, Use of P-Nitrophenyl Phosphate as the Substrate in Determination of Serum Acid Phosphatase, Amer. J. Clin. Pathol. 17:571 (1947).Google Scholar
- 11.E.H. Cooper, Personal Communication (1978).Google Scholar